Bosentan: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: Endothelin receptor antagonists *Dosage Forms: *Routes of Administration: Oral *Common Trade Names: Tracleer ==Adult Dosing== * 62.5-125mg PO BID =...") |
(edited dosage forms, strengths, routes of administration) |
||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: Endothelin receptor antagonists | *Type: Endothelin receptor antagonists | ||
*Dosage Forms: | *Dosage Forms: tablet, tablet for oral suspension | ||
*Routes of Administration: | *Dosage Strengths: tablet: 62.5, 125 mg; tablet for oral suspension: 32mg | ||
*Routes of Administration: PO | |||
*Common Trade Names: Tracleer | *Common Trade Names: Tracleer | ||
Revision as of 23:08, 11 October 2017
Administration
- Type: Endothelin receptor antagonists
- Dosage Forms: tablet, tablet for oral suspension
- Dosage Strengths: tablet: 62.5, 125 mg; tablet for oral suspension: 32mg
- Routes of Administration: PO
- Common Trade Names: Tracleer
Adult Dosing
- 62.5-125mg PO BID
Pediatric Dosing
Safety/efficacy not established
Special Populations
- Pregnancy Rating: X
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing:
- Hepatic dosing: avoid in moderate-severe disease
Contraindications
- Allergy to class/drug
- Concomitant administration with cyclosporine A or glyburide
- Pregnancy or potential pregnancy
Adverse Reactions
Serious
- Anemia
- Cirrhosis, liver failure
- Oligozoospermia
- Edema, fluid retention
Common
- Anemia
- Respiratory tract infection
Pharmacology
- Half-life: 5h
- Metabolism: Hepatic: via CYP3A4 and CYP2C9
- Excretion: Biliary, renal
Mechanism of Action
- Dual endothelin receptor antagonist, inhibits vasoconstriction --> vasodilation